Corvus Pharmaceu - CRVS STOCK NEWS

Corvus Pharmaceuticals announced a strategic collaboration with Angel Pharmaceuticals, securing a 49.7% equity stake to enhance its oncology pipeline development in China. Angel, a new biopharmaceutical company, aims to address serious diseases and launches with a $41 million financing, valuing it at $106 million. The collaboration allows for the development of three clinical-stage candidates and global BTK inhibitor programs. Clinical trials for these candidates are expected to commence within 12 to 18 months, leveraging a partnership with prominent Chinese investors and a talented local team.

Corvus Pharmaceuticals (CRVS) announced the completion of enrollment for the first three cohorts of its Phase 1 study for CPI-006, a novel immunotherapy targeting COVID-19. The data indicates a dose-response effect with prolonged high titers of SARS-CoV-2 specific antibodies at 56 days in the 1.0 mg/kg cohort. All treated patients showed increased memory B and T cells, and no drug-related safety issues were reported. Final cohort enrollment is underway, and a pivotal study is planned by year-end. Results are expected at the upcoming SITC meeting in November.

Corvus Pharmaceuticals (CRVS) announced new data from its collaboration with Genentech during the ESMO Virtual Congress 2020. The data focuses on ciforadenant combined with atezolizumab for treating non-small cell lung cancer (NSCLC). In a small study, patients showed longer disease control and overall survival compared to chemotherapy. The median overall survival was 11.5 months for the combination group versus 9.4 months for chemotherapy. Safety data indicated fewer adverse events. Corvus aims to advance ciforadenant into pivotal studies for advanced refractory renal cell cancer.

Corvus Pharmaceuticals (NASDAQ: CRVS) announced promising results from its Phase 1 study of CPI-006 as an immunotherapy for COVID-19. Patients in the first two cohorts exhibited significant antibody responses within 7 days, with neutralizing antibody levels rising to >1:200,000 by day 28. All treated patients showed clinical improvement and were discharged without safety issues. The study has enrolled 30 patients, with plans for an FDA meeting to discuss future pivotal studies. CPI-006 aims to activate the immune system potentially offering long-term immunity against SARS-CoV-2.

Corvus Pharmaceuticals (NASDAQ: CRVS) announced its participation in two upcoming investor conferences. The company will present at the HC Wainwright 22nd Annual Investment Conference on September 14, 2020, at 4:00 PM ET, and at the Cantor Virtual Healthcare Conference on September 17, 2020, at 4:40 PM ET. Both presentations will be available via webcast for 90 days on the Corvus website. Corvus is focused on developing innovative therapies for cancer and is currently advancing multiple clinical trials.

Corvus Pharmaceuticals (NASDAQ: CRVS) will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11 from 2:55-3:25pm ET. A live webcast will be available for 90 days post-event via the Corvus website.

The company is focused on innovative cancer treatments, studying lead candidates CPI-444 and CPI-006 in various clinical trials. Their research also explores CPI-818 for T-cell lymphomas and CPI-006 for COVID-19.

Corvus Pharmaceuticals (NASDAQ: CRVS) reported its Q2 2020 financial results, highlighting progress in its oncology programs, particularly ciforadenant, which showed a 17% objective response rate in a subset of renal cell carcinoma patients. The company plans to discuss a pivotal study with the FDA. Additionally, they initiated a Phase 1 study for CPI-006 targeting COVID-19, with early results indicating a favorable antibody response. Financially, Corvus ended Q2 with $59.3 million in cash, down from $78.0 million at year-end 2019, and reported a net loss of $10.6 million, an improvement from $13.0 million in Q2 2019.

Corvus Pharmaceuticals (NASDAQ: CRVS) announced a conference call on July 30, 2020, at 4:30 pm ET to discuss its business update and second quarter 2020 financial results. The call can be accessed via a toll-free number or by webcast through the investor relations section of their website. Corvus is a clinical-stage biopharmaceutical firm focused on cancer therapies, with key products including ciforadenant, CPI-006, and CPI-818 currently in various clinical trials, including studies for COVID-19 treatment.

Corvus Pharmaceuticals (NASDAQ: CRVS) has initiated a Phase 1 study to assess its novel immunotherapy, CPI-006, for treating COVID-19. The trial aims to enroll up to 30 patients with mild to moderate symptoms, following FDA acceptance of its IND application. CPI-006 has shown promise in activating B cells and inducing an antibody response in previous cancer studies. Early results from a patient with advanced cancer and COVID-19 demonstrated high levels of anti-SARS-CoV-2 antibodies and increased memory B cells post-treatment. Corvus plans to evaluate the efficacy and safety of CPI-006 and may pursue broader studies based on results.